Table 31Study quality assessment, KQ5, lung cancer

StudyProspective designPrespecified hypotheses about relation of marker to outcomeLarge, well-defined, representative study populationMarker assay methods well-describedBlinded assessment of marker in relation to outcomeHomogeneous treatment(s), either randomized or rule-based selectionLow rate of missing data (≤ 15%)Sufficiently long follow-upWell-described, well-conducted multivariate analysis of outcome: 1) clear candidate variable selection, 2) clear, appropriate model-building guidelines, 3) assumptions tested, 4) standard prognostic variables included, 5) continuous variables well handled, 6) validation
Koukourakis et al., 1999NNNY?YY??????N
Cappuzzo et al., 2005YN?Y?YN??????N
Hirsch et al., 2005YN?Y?YN??N???N
Saad et al., 2004NNNYYYYAC: 52 ± 20 mo;
BAC: 40 ± 17 mo
Cappuzzo et al., 2007YYNY?YY≥ 4 wkNA
Daniele et al., 2007NNNY?YYmed 14.8 mosNA
Krug et al., 2005YNNN?YY?NA
Pelosi et al., 2005NNYY?YYNET/NSCLC 53.3 ± 53.6 mo/: 72.6 ± 49.3 mosNA
Langer et al., 2004YNNN?YYmed 34 mosNA
Cappuzzo et al., 2003YYNY?YY?NA
Koukourakis et al., 2000NNNY?YYmed 46 mosNA
Graziano et al., 1998YYNN?YN?NA
Pfeiffer et al., 1996NNNY?YY66 mos (40–119)NA

Abbreviations: AC: adenocarcinoma; BAC: bronchoalveolar carcinoma; NSCLC: non-small cell lung cancer

From: 3, Results and Conclusions

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.